The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | NEST-1: neoadjuvant botensilimab and balstilimab in colorectal cancer
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, discusses the Phase II NEST-1 trial (NCT05571293) of neoadjuvant botensilimab, a CTLA-4 inhibitor, plus balstilimab, a PD-1 inhibitor, in patients with resectable colorectal cancer. Pathologic responses were promising in patients, especially in patients with microsatellite instability-high (MSI-H) tumors. The study supports further exploration of immunotherapy duration and watch-and-wait strategies for MSI-H patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The next one trial is not an interesting trial because it’s a new combination, new anti-CTLA-4 and also PD-1. And this combination is great to know new data in terms of the efficacy and also safety for facing with proficient colorectal cancer. So there is a clear unmet need for the colorectal cancer because more than 80% of the cases mainly in advanced disease, are proficient tumor. So the new data is in line with the previous data presented this year in ASCO GI 2024, with pathological complete response in 71% of the cases and 100% and deficient or MMR instability microsatellite patients...
The next one trial is not an interesting trial because it’s a new combination, new anti-CTLA-4 and also PD-1. And this combination is great to know new data in terms of the efficacy and also safety for facing with proficient colorectal cancer. So there is a clear unmet need for the colorectal cancer because more than 80% of the cases mainly in advanced disease, are proficient tumor. So the new data is in line with the previous data presented this year in ASCO GI 2024, with pathological complete response in 71% of the cases and 100% and deficient or MMR instability microsatellite patients. So I think that we need to longer follow up and also probably how to define the best way or the strategy for our proficient patients in non-metastatic colorectal cancer.
Read more...
